Potent and selective CXCR2 chemokine receptor antagonist (IC50
= 22 nM) that displays > 150-fold selectivity over CXCR1 receptors. Causes inhibition of IL-8 and GROα
-mediated calcium mobilization in HL60 cells (IC50
values are 8 and 10 nM respectively). Prevents IL-8-induced neutrophil chemotaxis in vitro
and sequestration in vivo
. Inhibits HIV replication in lymphocytes and macrophages.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.
White et al.
Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy.
Lane et al.
Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen a (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.
Catusse et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 225002 include:
Showing Results 1 - 6 of 6